Publication
The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (10)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 10
- cancerInfantile Fibrosarcomacivic_curation1.00
- cancerSarcomacivic_curation1.00
- cancerSpindle Cell Sarcomacivic_curation1.00
- drugLarotrectinibcivic_curation1.00
- geneNTRK1civic_curation1.00
- geneNTRK3civic_curation1.00
- variantNTRK1 Fusioncivic_curation1.00
- variantNTRK1 Fusioncivic_curation1.00
- variantNTRK1 Fusioncivic_curation1.00
- variantNTRK3 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 30204247
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NTRK3 Fusion1 | ||||||||
| Larotrectinib | Infantile FibrosarcomaALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID7418In a pediatric phase 1 trial (NCT02637687) after initial chemotherapy failure, two ETV6-NTRK3 positive children (2 year old and 5 month old) were treated with Larotrectinib, resulting in reduced tumor… (full text at CIViC) PMID 30204247 · DuBois et al., 2018 · Open in CIViC | civic |
| NTRK1 Fusion1 | ||||||||
| Larotrectinib | Infantile FibrosarcomaALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID8865In a pediatric phase 1 trial (NCT02637687), a 2 year old with infantile fibrosarcoma of the shoulder harbored the SQSTM1-NTRK1 fusion. After two surgical resections and multiple rounds of chemotherapy… (full text at CIViC) PMID 30204247 · DuBois et al., 2018 · Open in CIViC | civic |
| NTRK1 Fusion1 | ||||||||
| Larotrectinib | Sarcoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID7420In a pediatric phase 1 trial (NCT02637687), a boy aged 15 months with soft tissue sarcoma of the right upper thigh harbored the PDE4DIP-NTRK1 fusion. After resection and the failure of initial chemoth… (full text at CIViC) PMID 30204247 · DuBois et al., 2018 · Open in CIViC | civic |
| NTRK1 Fusion1 | ||||||||
| Larotrectinib | Spindle Cell Sarcoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID7419In a pediatric phase 1 trial (NCT02637687), a 12-year-old boy with TPM3-NTRK1 fusion was treated with Larotrectinib as first line treatment as no standard treatment options were available. Following a… (full text at CIViC) PMID 30204247 · DuBois et al., 2018 · Open in CIViC | civic |